Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2013

View Archived Issues

Inhibition of a kinase to prevent maladaptive changes during cardiac reperfusion

SUVN-911 demonstrates antidepressant activity in vivo

Phase III studies of clonidine gel for painful diabetic neuropathy to begin next year

Exelixis begins phase II trial of cabozantinib plus abiraterone/prednisone in prostate cancer

Sanofi Pasteur analyzes safety data for the CYD-TDV dengue vaccine

ARISE trial of sebelipase alfa reaches full enrollment

Celldex Therapeutics initiates study of glembatumumab vedotin for triple-negative breast cancer

AB Science initiates phase III study of masitinib for colorectal cancer

Medivation and Astellas begin phase III PROSPER study of enzalutamide

Lexicon Pharmaceuticals reports topline results from phase II LX-1033 study

FDA clears California Stem Cell's application for phase III cancer stem cell trial

Durata Therapeutics submits MAA for dalbavancin

Navidea Biopharmaceuticals begins phase III registration program for NAV-5001

Preliminary phase I results show safety and efficacy for PVSRIPO in patients with glioblastoma

Chinese researchers disclose new HDAC inhibitors for cancer

Tragara Pharmaceuticals begins trial of TG-02 in combination with carfilzomib

New CTLA-4 variants selected by MedImmune

Blaze Bioscience conducts financing round to support development of BLZ-100

The Albert Einstein College of Medicine patents new tuberculosis vaccine

Cancer Research Technology divulges new Chk1 inhibitors for cancer

Alphavirus-based vaccine encoding PSA tested in mouse model of prostate cancer

Novartis patents novel protein kinase inhibitors for cancer and viral infections

Telormedix raises funds to support phase II trial of TMX-101

Vivalis presents new agents for HCV infection

Teva and Takeda announce Japanese agreement for glatiramer acetate

Pharmacyclics describes novel BTK inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...